Krystal Biotech (KRYS) EPS (Basic) (2016 - 2026)

Krystal Biotech has reported EPS (Basic) for 11 years, with the latest figure at $1.85 in Q2 2026.

• EPS (Basic) for Q2 2026 came in at $1.85, up 39.88% year-over-year; the trailing twelve-month figure through Jun 2026 was $8.18 (up 61.13% YoY), and the FY2025 annual result was $7.08, up 126.94% from the prior year.
• EPS (Basic) declined to $1.85 in Q2 2026, from $1.91 in the prior quarter.
• Over five years, EPS (Basic) peaked at $2.88 in Q3 2023 and troughed at -$4.45 in Q1 2023.
• A 5-year average of $0.11 and a median of $0.75 in 2024 frame the typical range for EPS (Basic).
• The widest annual swing landed in 2022, when EPS (Basic) plunged 79.18%; it then surged 3661.03% in 2025.
• A 5-year view of EPS (Basic) shows it stood at -$1.33 in 2022, then jumped by 123.98% to $0.32 in 2023, then surged by 397.29% to $1.59 in 2024, then increased by 11.54% to $1.78 in 2025, then grew by 4.46% to $1.85 in 2026.
• Per Business Quant data, the three most recent EPS (Basic) figures were $1.85 in Q2 2026, $1.91 in Q1 2026, and $1.78 in Q4 2025.